PodParley PodParley
PodParley
S9 Ep15: FDA Approval Insights: Glofitamab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma episode artwork

EPISODE · Aug 3, 2023 · 21 MIN

S9 Ep15: FDA Approval Insights: Glofitamab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

from OncLive® On Air · host OncLive® On Air

Dr Carlo-Stella discusses the FDA approval of glofitamab in relapsed/refractory DLBCL, key efficacy and safety findings from the NP30179 trial, and the benefits of glofitamab’s mechanism of action.

Episode metadata supplied by the publisher feed · Published Aug 3, 2023

Embed this episode

NOW PLAYING

S9 Ep15: FDA Approval Insights: Glofitamab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

0:00 21:26

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of OncLive® On Air?

This episode is 21 minutes long.

When was this OncLive® On Air episode published?

This episode was published on August 3, 2023.

Can I download this OncLive® On Air episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!